LEAP-002: Placebo-Controlled Phase III Trial of Lenvatinib ± Pembrolizumab as First-line Therapy for Advanced HCC

September 9-13, 2022; Paris, France
Primary results from the phase III LEAP-002 study showed that first-line treatment with lenvatinib plus pembrolizumab was not superior to lenvatinib plus placebo in patients with advanced hepatocellular carcinoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 229 KB
Released: September 19, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Exelixis, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Expert commentary on surveillance and screening strategies in HCC, from Clinical Care Options (CCO)

David E. Kaplan, MD, MSc Released: October 14, 2022

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

Phase I/II ReFocus: RLY-4008 in patients with FGFR inhibitor-naive cholangiocarcinoma with FGFR2 alterations, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings